{"preliminary_commentary":{"by_channel":{"podcast":8,"youtube":6,"x_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06161025\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"REJOICE-Ovarian01","nct_id":"NCT06161025","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=rejoice-ovarian01-nct06161025. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will be randomized to receive intravenous R-DXd administered at a dose of 4.8 mg/kg every 3 weeks (Q3W).","label":"Part A: R-DXd 4.8mg/kg Q3W","type":"EXPERIMENTAL"},{"description":"Participants will be randomized to receive intravenous R-DXd administered at a dose of 5.6 mg/kg every 3 weeks (Q3W).","label":"Part A: R-DXd 5.6 mg/kg Q3W","type":"EXPERIMENTAL"},{"description":"Participants will be randomized to receive intravenous R-DXd administered at a dose of 6.4 mg/kg every 3 weeks (Q3W).","label":"Part A: R-DXd 6.4 mg/kg Q3W","type":"EXPERIMENTAL"},{"description":"Participants will be randomized to receive intravenous R-DXd administered at the Recommended Phase 3 Dose (RP3D) every 3 weeks (Q3W).","label":"Part B: R-DXd RP3D Q3W","type":"EXPERIMENTAL"},{"description":"Participants will be randomized to receive intravenous treatment with investigator's choice of paclitaxel, pegylated liposomal doxorubicin (PLD), or topotecan.","label":"Part B: Investigator's Choice","type":"ACTIVE_COMPARATOR"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2030-04-30","type":"ESTIMATED"},"conditions":["Solid Cancer"],"enrollment":{"count":860,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"R-DXd","otherNames":["DS-6000a"],"type":"DRUG"},{"name":"Paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Topotecan","otherNames":[],"type":"DRUG"},{"name":"PLD","otherNames":["Pegylated Liposomal Doxorubicin"],"type":"DRUG"}],"last_update":"2026-10-26","lead_sponsor":"Daiichi Sankyo","official_title":"A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2028-02-29","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Assessment (Part A)","timeFrame":"From date of randomization to data cut off, up to 18 months"},{"measure":"Progression-free Survival (PFS) Based on BICR Assessment (Part B)","timeFrame":"From date of randomization to data cut off, up to 26 months"}],"references":[],"start_date":{"date":"2024-02-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","url":"https://clinicaltrials.gov/study/NCT06161025"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/rejoice-ovarian01-nct06161025"}